Triveni Bio Raises $65M Series C Co-Led by Ascenta, Henderson Investors

Triveni Bio, a clinical-stage biotechnology company developing novel antibody treatments for immunological and inflammatory disorders, has closed a $65 million... Read More

The post Triveni Bio Raises $65M Series C Co-Led by Ascenta, Henderson Investors appeared first on citybiz.